Intelligence Feed event · Equity · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth

    Question

    CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth

    Direct answer

    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with quarterly product sales reaching $76 million, up 78% from the prior quarter. The U.S. FDA granted label expansion allowing treatment in pediatric patients aged 2 and above, broadening the eligible population for the commercial therapy developed with Vertex Pharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-label-and-posts-78-sequential-revenue-growth-bfd8ff

    EQUITY
    CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with quarterly product sales reaching $76 million, up 78% from the prior quarter. The U.S. FDA granted label expansion allowing treatment in pediatric patients aged 2 and above, broadening the eligible population for the commercial therapy developed with Vertex Pharmaceuticals.
    CRSPVRTX
    Impact
    62
    SEP 9
    SIG
    85%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with quarterly product sales reaching $76 million, up 78% from the prior quarter. The U.S. FDA granted label expansion allowing treatment in pediatric patients aged 2 and above, broadening the eligible population for the commercial therapy developed with Vertex Pharmaceuticals.
    → Pediatric label expansion broadens the addressable patient pool for Casgevy, accelerating commercial cash flow generation for CRSP.
    Impact
    CRISPR Therapeutics disclosed commercial progress for its gene-editing therapy Casgevy, with quarterly product sales reaching $76 million, up 78% from the prior quarter. The U.S. FDA granted label expansion allowing treatment in pediatric patients aged 2 and above, broadening the eligible population for the commercial therapy developed with Vertex Pharmaceuticals.
    Affected
    CRSPVRTX
    Transmission
    Pediatric label expansion broadens the addressable patient pool for Casgevy, accelerating commercial cash flow generation for CRSP.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial sales ramp and pediatric TAM expansionUp1-3mCasgevy quarterly sales reached $76M (+78% QoQ) with pediatric FDA approval.
    VRTXcommercial revenue share on Casgevy global salesUp1-3mVertex co-commercializes Casgevy with CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month